Brazil's ANSIVA raises safety issues in Covaxin production
Brazil’s medicines regulator has rejected an application from India’s Bharat Biotech for a certificate of Good Manufacturing Practices for its COVID-19 vaccine Covaxin, following an inspection of the company’s site in Hyderabad earlier this month.
The move, which does not affect Bharat Biotech’s application for emergency use authorization of the vaccine in Brazil, could potentially still delay its ability to supply doses of the COVID-19 vaccine to the country until the issue is resolved.
An inspection by the Agencia Nacional de Vigilancia Sanitari (ANVISA) from March 1-5 revealed issues related to Bharat Biotech’s manufacturing processes. According to the regulator, these issues could potentially risk the quality of the vaccine, and the action plan it sent was not sufficient to mitigate the risks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze